Cigna Corporation Stock News

The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern.

Although the revenue and EPS for Cigna (CI) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street esti

Cigna's (CI) Q1 results reflect strong organic growth in the Evernorth Health Services unit. It expects adjusted EPS of at least $28.40 for 2024, up from the earlier guidance of at least $28.25.

The Cigna Group (NYSE:CI ) Q1 2024 Earnings Call Transcript May 2, 2024 8:30 AM ET Company Participants Ralph Giacobbe - SVP of IR David Cordani - Chairman and CEO Brian Evanko - CFO, and President an

Cigna (CI) came out with quarterly earnings of $6.47 per share, beating the Zacks Consensus Estimate of $6.17 per share. This compares to earnings of $5.41 per share a year ago.

Cigna Group's stock CI, +0.04% rose 2.7% early Thursday, after the healthcare and insurance company posted better-than-expected first-quarter earnings and raised its guidance. The company had a net lo

Health insurer Cigna Group raised its annual profit forecast on Thursday, as lower-than-expected medical costs and strength in its pharmacy benefit management unit helped it beat first-quarter earning

Cigna Group (CI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The first-quarter results of Cigna (CI) are likely to reflect expanding commercial middle market memberships and growth in Cigna Healthcare profits.

Some of the managed care stocks have been beaten down quite badly in recent months, thanks in part to choppy industry dynamics. Indeed, swift policy shifts (lower Medicare rates), cybersecurity breach

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Besides Wall Street's top -and-bottom-line estimates for Cigna (CI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarte

Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June,

In the closing of the recent trading day, Cigna (CI) stood at $352.65, denoting a -0.15% change from the preceding trading day.

The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can ke